Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Drug Pricing topic
No spam. Unsubscribe anytime.
Senators press HHS secretary for full disclosure of "Trump RX" drug agreements; Kennedy cites trade secrets
Summary
Democrats demanded Secretary Robert Kennedy release written agreements with pharmaceutical companies tied to the administration's Trump RX program; Kennedy said NDAs and proprietary trade secrets limit disclosure but offered partial transparency while defending lower prices on covered drugs.
Democrats on the Senate Committee on Finance pressed Secretary Robert Kennedy to release written agreements the administration negotiated with pharmaceutical companies for the Trump RX program, calling the deals "sweatheart" agreements that deserve public scrutiny.
"Will you commit to releasing your written agreements with the pharmaceutical companies tomorrow?" one senator asked directly. Kennedy answered, "No, I will not," arguing the agreements contain proprietary information and trade secrets and that the statutory negotiation framework requires NDAs to secure company participation.
Members cited price comparisons and examples where Trump RX prices exceeded other U.S. retail options or international prices, and they repeatedly asked how the administration calculated claimed savings. Kennedy said the program covered a limited set of high-use brand medicines and that many covered products now have substantially lower prices under the agreements. "For those drugs we do," Kennedy said when asked whether the United States now pays lower prices for covered medicines.
Senators also raised the related policy lever of tariff relief — Kennedy said tariff exemptions tied to onshoring commitments could be rescinded if companies fail to produce in the United States within a year. Multiple senators warned that limited coverage (about 80 drugs on the platform) and eligibility rules mean many patients will not benefit from Trump RX.
The committee asked for the agreements and related documents to be made available to senators for oversight. Kennedy offered to provide non-proprietary summaries and argued full onshoring and price reductions are central to the administration's approach. The exchange ended without the committee securing full unredacted copies; members said they would continue pressing for transparency.
